Total Payments
$5,741
2024 Payments
$918.57
Companies
18
Transactions
140
Medicare Patients
281
Medicare Billing
$40,986
Payment Breakdown by Category
Food & Beverage$3,300 (57.5%)
Research$1,568 (27.3%)
Travel$823.95 (14.4%)
Education$48.84 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,300 | 132 | 57.5% |
| Unspecified | $1,568 | 6 | 27.3% |
| Travel and Lodging | $823.95 | 1 | 14.4% |
| Education | $48.84 | 1 | 0.9% |
Payments by Type
General
$4,173
134 transactions
Research
$1,568
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,568 | 6 | $0 (2018) |
| Avanir Pharmaceuticals, Inc. | $1,292 | 10 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $744.82 | 33 | $0 (2024) |
| Alkermes, Inc. | $511.12 | 19 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $460.20 | 14 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $362.56 | 8 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $212.24 | 17 | $0 (2024) |
| ITI, Inc. | $185.24 | 8 | $0 (2023) |
| Sunovion Pharmaceuticals Inc. | $74.49 | 5 | $0 (2022) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $71.85 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $918.57 | 50 | Alkermes, Inc. ($251.99) |
| 2023 | $1,003 | 32 | ACADIA Pharmaceuticals Inc ($267.46) |
| 2022 | $303.83 | 11 | Alkermes, Inc. ($177.57) |
| 2021 | $174.83 | 4 | Janssen Pharmaceuticals, Inc ($122.78) |
| 2020 | $16.93 | 1 | Janssen Pharmaceuticals, Inc ($16.93) |
| 2019 | $1,139 | 11 | Avanir Pharmaceuticals, Inc. ($1,039) |
| 2018 | $1,716 | 15 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($1,568) |
| 2017 | $468.94 | 16 | Avanir Pharmaceuticals, Inc. ($236.37) |
All Payment Transactions
140 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $6.57 | General |
| Category: Central Nervous System | ||||||
| 12/18/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $25.92 | General |
| Category: CNS | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $17.46 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/06/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: Central Nervous System | ||||||
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $17.43 | General |
| Category: PSYCHIATRY | ||||||
| 11/21/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $34.69 | General |
| Category: Neuropsychiatry | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $16.05 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/16/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $15.86 | General |
| Category: Central Nervous System | ||||||
| 11/16/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $11.67 | General |
| Category: Neurology | ||||||
| 11/13/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $29.35 | General |
| Category: Neuropsychiatry | ||||||
| 11/13/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $24.19 | General |
| Category: CNS | ||||||
| 11/06/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: SCHIZOPHRENIA | ||||||
| 10/30/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $14.02 | General |
| Category: PSYCHIATRY | ||||||
| 10/02/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: SCHIZOPHRENIA | ||||||
| 09/25/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $17.86 | General |
| Category: Neuroscience | ||||||
| 09/17/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $24.09 | General |
| Category: CNS | ||||||
| 08/28/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: Neuroscience | ||||||
| 08/28/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $14.96 | General |
| 08/26/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $1.66 | General |
| Category: Central Nervous System | ||||||
| 08/21/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $29.91 | General |
| Category: CNS | ||||||
| 08/21/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $15.08 | General |
| Category: Central Nervous System | ||||||
| 08/13/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: Neuroscience | ||||||
| 08/08/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $30.02 | General |
| Category: Neuropsychiatry | ||||||
| 07/17/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $11.35 | General |
| Category: CNS | ||||||
| 07/16/2024 | Noven Therapeutics, LLC | Secuado (Drug), Xelstrym | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: CNS Psychiatry | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM, FIXED-DOSE TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE OPC34712 IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMERS TYPE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,568 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 11 | 16 | $2,332 | $982.08 |
| 2022 | 1 | 20 | 74 | $16,079 | $5,570 |
| 2021 | 4 | 77 | 175 | $35,457 | $12,799 |
| 2020 | 5 | 173 | 408 | $53,829 | $21,634 |
Total Patients
281
Total Services
673
Medicare Billing
$40,986
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 16 | $2,332 | $982.08 | 42.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 20 | 74 | $16,079 | $5,570 | 34.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 29 | 94 | $20,424 | $6,860 | 33.6% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2021 | 18 | 18 | $5,745 | $2,430 | 42.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 19 | 35 | $5,239 | $2,032 | 38.8% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 11 | 28 | $4,049 | $1,478 | 36.5% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 36 | 105 | $10,761 | $5,397 | 50.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 24 | 74 | $14,715 | $4,885 | 33.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 34 | 79 | $9,993 | $3,297 | 33.0% |
| 90833 | Psychotherapy, 30 minutes | Facility | 2020 | 22 | 51 | $5,245 | $2,526 | 48.2% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2020 | 19 | 19 | $4,856 | $2,124 | 43.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 20 | 48 | $5,346 | $1,740 | 32.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 18 | 32 | $2,912 | $1,666 | 57.2% |
About Dr. Kulsoom Junaid, M.D
Dr. Kulsoom Junaid, M.D is a Psychiatry healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1497827968.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kulsoom Junaid, M.D has received a total of $5,741 in payments from pharmaceutical and medical device companies, with $918.57 received in 2024. These payments were reported across 140 transactions from 18 companies. The most common payment nature is "Food and Beverage" ($3,300).
As a Medicare-enrolled provider, Junaid has provided services to 281 Medicare beneficiaries, totaling 673 services with total Medicare billing of $40,986. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Saint Louis, MO
- Active Since 11/13/2006
- Last Updated 05/17/2021
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1497827968
Products in Payments
- INVEGA SUSTENNA (Drug) $607.29
- INGREZZA (Drug) $460.20
- NUPLAZID (Drug) $362.56
- ARISTADA (Drug) $333.25
- NUEDEXTA (Drug) $268.63
- CAPLYTA (Drug) $257.09
- Austedo XR (Drug) $166.98
- LYBALVI (Drug) $133.88
- INVEGA TRINZA (Drug) $77.14
- LATUDA (Drug) $74.49
- PERSERIS (Drug) $66.75
- SPRAVATO (Drug) $60.39
- Aristada 441 mg (Drug) $43.99
- COBENFY (Drug) $33.51
- UZEDY (Drug) $32.43
- FANAPT (Drug) $31.72
- REXULTI (Drug) $25.73
- Briviact (Drug) $18.03
- Xelstrym (Drug) $16.19
- ADUHELM (Biological) $15.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Saint Louis
Dr. Mohd Malik, M.d, M.D
Psychiatry — Payments: $1.8M
Psychiatry $1.8M
Adam Sky, Md, MD
Psychiatry — Payments: $1.4M
Psychiatry $1.4M
Dr. Junaid Syed, M.d, M.D
Psychiatry — Payments: $1.1M
Psychiatry $1.1M
Dr. Michael Stotler, Md, MD
Psychiatry — Payments: $299,451
Psychiatry $299,451
Dr. Naji Chaaya Salloum, M.d, M.D
Psychiatry — Payments: $236,374
Psychiatry $236,374
Dr. Devnandini Rastogi, Md, MD
Psychiatry — Payments: $230,240
Psychiatry $230,240